<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04025788</url>
  </required_header>
  <id_info>
    <org_study_id>2018-01420</org_study_id>
    <nct_id>NCT04025788</nct_id>
  </id_info>
  <brief_title>BIOSOLVE-IV Magmaris Swiss Satellite Registry</brief_title>
  <official_title>BIOTRONIKS-Safety and Performance in de Novo Lesion of Native Coronary Arteries With Magmaris (BIOSOLVE)-IV Magmaris Swiss Satellite Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BIOSOLVE-IV Magmaris Swiss Satellite Registry is a prospective, single-arm, multicenter,&#xD;
      nationwide open label registry. It is planned to enroll 200 subjects in up to 12&#xD;
      participating sites in Switzerland. After percutaneous coronary intervention (PCI) with the&#xD;
      Magmaris scaffold and signature of the informed consent form, all subjects will be followed&#xD;
      through hospital discharge and will undergo follow up evaluations at 6, 12 and 24 months post&#xD;
      procedure. The follow up evaluations, part of the standard care can be either performed on&#xD;
      site (12 months) or by phone (6 and 24 months) and according to routine clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Target Lesion Failure at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Target Lesion Failure (TLF, a composite of cardiac death, target vessel Q-wave or non-Q wave Myocardial Infarction, and clinically driven Target Lesion Revascularization) at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure</measure>
    <time_frame>6 months and annually thereafter up to 2 years post-procedure</time_frame>
    <description>Target Lesion Failure (TLF) at 6, 12 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven Target Lesion Revascularization</measure>
    <time_frame>6, 12 months and 24 months post-procedure</time_frame>
    <description>Clinically driven Target Lesion Revascularization (TLR) at 6, 12 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven Target Vessel Revascularization</measure>
    <time_frame>6, 12 months and 24 months post-procedure</time_frame>
    <description>Clinically driven Target Vessel Revascularization (TVR) at 6, 12 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>6, 12 and 24 months post-procedure</time_frame>
    <description>Cardiac death at 6, 12 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Myocardial Infarction</measure>
    <time_frame>6, 12 and 24 months post-procedure</time_frame>
    <description>Target Vessel Myocardial Infarction (MI) at 6, 12 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scaffold thrombosis</measure>
    <time_frame>6, 12 and 24 months post-procedure</time_frame>
    <description>Scaffold thrombosis at 6, 12 and 24 months</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magmaris Resorbable Magnesium Scaffold (RMS)</intervention_name>
    <description>Subjects will undergo a percutaneous coronary intervention for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of two single de novo lesions in two separate major epicardial vessels are allowed.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        BIOSOLVE-IV Magmaris Swiss Satellite Registry will include male and female subjects&#xD;
        requiring a treatment of de novo coronary artery lesions with Magmaris.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is ≥18 years of age&#xD;
&#xD;
          -  Subject must be willing to sign a Patient Informed Consent&#xD;
&#xD;
          -  Symptomatic coronary artery disease&#xD;
&#xD;
          -  Subject with a maximum of two single de novo lesions in two different major epicardial&#xD;
             vessels&#xD;
&#xD;
          -  Target lesion length ≤ 21 mm by QCA or by visual estimation&#xD;
&#xD;
          -  Target lesion stenosis &gt;50% and &lt;100% by visual estimation, and TIMI flow ≥1.&#xD;
&#xD;
          -  Subject is eligible for Dual Anti Platelet Therapy (DAPT)&#xD;
&#xD;
          -  Reference vessel diameter between 2.7-3.7 mm by visual estimation, depending on the&#xD;
             scaffold size used&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and/or breastfeeding females or females who intend to become pregnant during&#xD;
             the time of the registry&#xD;
&#xD;
          -  Known allergies to: Acetylsalicylic Acid (ASA), clopidogrel, heparin or any other&#xD;
             anticoagulant /antiplatelet required for PCI, contrast medium, sirolimus, or similar&#xD;
             drugs; or the scaffold materials including Magnesium, Yttrium, Neodymium, Zirconium,&#xD;
             Gadolinium, Dysprosium, Tantalum that cannot be adequately pre-medicated&#xD;
&#xD;
          -  Subjects on dialysis&#xD;
&#xD;
          -  Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with&#xD;
             acute ST elevation myocardial infarction (STEMI) within 72 hours prior to the index&#xD;
             procedure. Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for&#xD;
             study enrollment&#xD;
&#xD;
          -  Documented left ventricular ejection fraction (LVEF) ≤30% as documented within maximum&#xD;
             6 months prior to the procedure&#xD;
&#xD;
          -  Heavily calcified or extremely tortuous lesions&#xD;
&#xD;
          -  Bifurcation lesion requiring side branch intervention, if side branches &gt;2 mm in&#xD;
             diameter are involved&#xD;
&#xD;
          -  Restenotic target lesion&#xD;
&#xD;
          -  Thrombus in target vessel&#xD;
&#xD;
          -  Target lesion is located in or supplied by a diseased (defined as vessel irregularity&#xD;
             per angiogram and &gt;20% stenosed lesion by visual estimation) arterial or venous bypass&#xD;
             graft&#xD;
&#xD;
          -  Left main coronary artery disease&#xD;
&#xD;
          -  Ostial target lesion (within 5.0 mm of vessel origin)&#xD;
&#xD;
          -  Target vessel (including side branches) has second lesion which requires treatment&#xD;
             according to the investigator's discretion&#xD;
&#xD;
          -  Unsuccessful pre-dilatation, defined as residual stenosis rate &gt;20% by visual&#xD;
             estimation and/or angiographic complications (e.g. distal embolization, side branch&#xD;
             closure, extensive dissections)&#xD;
&#xD;
          -  Planned surgery within 6 months of PCI unless dual antiplatelet therapy will be&#xD;
             maintained&#xD;
&#xD;
          -  Currently participating in another study and primary endpoint is not reached yet&#xD;
&#xD;
          -  Planned interventional treatment of any non-target vessel within 30 days post&#xD;
             procedure&#xD;
&#xD;
          -  Planned intervention of the target vessel within 6-month after the index procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan F Iglesias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Geneva</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan F Iglesias, MD</last_name>
    <phone>+41 79 553 34 67</phone>
    <email>JuanFernando.Iglesias@hcuge.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Unité de Cardiologie interventionnelle, Service de cardiologie, Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Genève</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan F Iglesias, MD</last_name>
      <phone>+41 22 372 72 00</phone>
      <email>JuanFernando.Iglesias@hcuge.ch</email>
    </contact>
    <contact_backup>
      <last_name>Marco Roffi, Prof</last_name>
      <phone>+41 22 372 72 00</phone>
      <email>Marco.Roffi@hcuge.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baselland, Kardiologie</name>
      <address>
        <city>Liestal</city>
        <zip>4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregor Leibundgut, MD</last_name>
      <phone>+41 61 925 23 65</phone>
      <email>Gregor.Leibundgut@ksbl.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ensemble Hospitalier de la Côte, Hôpital de Morges, Cardiologie</name>
      <address>
        <city>Morges</city>
        <zip>1110</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann Roux, MD</last_name>
      <phone>+41 21 804 21 38</phone>
      <email>yann.roux@ehc.vd.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Interventionnelle Kardiologie, Kantonspital St.Gallen, Kardiologie</name>
      <address>
        <city>Saint Gallen</city>
        <zip>9000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucas Joerg, MD</last_name>
      <phone>+41 71 494 10 51</phone>
      <email>Lucas.Joerg@kssg.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital du Valais Sion</name>
      <address>
        <city>Sion</city>
        <zip>1950</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxime Tapponnier, MD</last_name>
      <phone>+41 27 603 45 82</phone>
      <email>Maxime.tapponnier@hopitalvs.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HFR Fribourg, Cardiologie</name>
      <address>
        <city>Villars-sur-Glâne</city>
        <zip>1752</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane Cook, Prof</last_name>
      <phone>+41 26 306 38 00</phone>
      <email>stephane.cook@unifr.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>IGLESIAS Juan Fernando</investigator_full_name>
    <investigator_title>Medical Doctor, Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

